Abingdon Health PLC Manufacturing Agreement with Bioporto A/S
July 05 2021 - 1:00AM
RNS Non-Regulatory
TIDMABDX
Abingdon Health PLC
05 July 2021
Manufacturing Agreement with Bioporto A/S
York, U.K. 5 July 2021: Abingdon Health plc (AIM: ABDX)
("Abingdon" or "the Company"), a leading international developer
and manufacturer of high quality and effective rapid tests, today
announces that it has signed a manufacturing and supply agreement
with Bioporto A/S (CPH: BIOPOR), an in vitro diagnostics company
that provides tests and antibodies to clinicians and researchers
around the world.
Under the terms of the 10-year agreement, Abingdon will
manufacture the lateral flow strips for Bioporto's Generic Rapid
Assay Device (gRAD) platform, the company's proprietary patented
technology for rapid lateral flow test development. The test which
has completed technical transfer will be manufactured by Abingdon
Health at its Doncaster facility, following the Company's expansion
of its manufacturing capacity. This will provide Bioporto A/S with
immediate access to high volume manufacturing to meet their
anticipated global demand for its product.
Leigh Thomas, SVP Director of Global Sales of Abingdon Health,
commented: " We are delighted to be supporting Bioporto with access
to Abingdon's high volume manufacturing capability. We have built a
strong relationship with the team during the transfer of their
exceptional lateral flow products into Abingdon Health and are
pleased to have secured this long-term manufacturing arrangement.
We are pleased to be able to provide our manufacturing expertise
and growing capacity to help the deployment of high quality rapid
lateral flow tests to the international markets."
Enquiries:
Abingdon Health plc
Chris Yates Chief Executive Officer Via Consilium
Dr Chris Hand Non-Executive Chairman
Melanie Ross Chief Financial Officer
Consilium Financial PR Tel: +44 (0) 7720 088 468
Matthew Neal abingdonhealth@consilium-comms.com
Mary-Jane Elliott
Davide Salvi
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of
high-quality rapid tests across all industry sectors, including
healthcare and COVID-19. Abingdon is the partner of choice for a
growing global customer base and takes projects from initial
concept through to routine and large-scale manufacturing and has
also developed and marketed its own labelled tests.
The Company offers product development, regulatory support,
technology transfer and manufacturing services for customers
looking to develop new assays or transfer existing laboratory-based
assays to a lateral flow format. Abingdon Health aims to support
the increase in need for rapid results across many industries and
locations and produces lateral flow tests in areas such as
infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes. This ability has a significant
role to play in improving life across the world. To support this
aim Abingdon Health has also developed AppDx(R), a customisable
image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York,
England.
https://www.abingdonhealth.com/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUSVKRAWUBRAR
(END) Dow Jones Newswires
July 05, 2021 02:00 ET (06:00 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Apr 2024 to May 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From May 2023 to May 2024